Experienced leader of drug discovery projects from target ID to IND in large pharma. In addition developed services for profiling kinases, ion channels and cellular readouts. Gained good working knowledge of PROTACs.
I have been fortunate in my career to work in large pharma bringing new medicines closer to patients and in tools-based vendors to develop CRO services for kinases, cell signaling, and biomarker discovery. I also held positions in business development for these vendors to place these services in the context of pharma’s needs. I also conducted several due diligence projects and worked with corporate to secure acquisitions of companies of technology platforms. Over the last few years I have built expertise in the repositioning of parked clinical assets with ML/AI companies or academics.
Discovery Sciences (550 FTEs) conducted all the early-stage drug discovery projects for small molecules, ASOs, and PROTACs from HTS to structural biology. As chief of staff, I oversaw the operational aspects of the department, managing governance meetings, oversight of the budget, and staff development in partnership with HR.
I collaborated with academic teams and ML/AI biotech companies to reposition “parked” Phase II clinical assets in rare diseases and neurological conditions. I identified technology gaps and emerging scientific areas and bought external projects to AZ or raised internal funding to secure three-year Post-Doc projects. I co-led an Incubator lab at AZ, housing several start-ups, and also served as a mentor/business consultant.
I provide insights into strategy development, go-to-market strategy, and technology fit for early-stage drug discovery (target ID to IND). In addition, I served as VP of R&D and CBO in start-ups. Member of SAB for several biotech companies.